Researchers report a shift in PK toward high-risk cases as new treatments for corneal ectasia and Fuchs dystrophy reduce low-risk procedures.

Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® ...

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first ...

WASHINGTON, Feb 20 (Reuters) - Biotech company Regenxbio (RGNX.O), opens new tab and the University of Pennsylvania on Friday convinced a U.S. appeals court to revive their patent lawsuit against ...

Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to decreased life expectancy and has no approved therapies. The disease is caused by ...

Minoxidil and finasteride are two FDA-approved medications considered the gold standard for treating hair loss. Other treatments like low-level light therapy, PRP injections, and supplements may also ...

A sweeping review of global research suggests that exercise—especially aerobic activities like running, swimming, and dancing—can be one of the most powerful ways to ease depression and anxiety.

PTC Therapeutics withdrew a New Drug Application for Translarna, a muscular dystrophy treatment, after the Food and Drug Administration indicated it would likely not grant approval. "FDA shared that ...

Researchers recently tried an experiment: Gather people who had the same kind of lung cancer and put them on the same type of treatments to fire up their immune systems. The only difference was that ...

Hair loss is stressful. In South Korea, it’s now being treated like a national crisis. President Lee Jae Myung recently called hair loss a “matter of survival” and went so far as to call for ...